MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Strand Life Sciences Introduces Liquid Biopsy Test to Enhance Cancer Diagnosis

NextEdge Admin

16 Sep 2024

2 min 16 sec

Reliance Industries Limited,Liquid Biopsy,precision medicine

Strand Life Sciences, a subsidiary of Reliance Industries Limited, announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test, designed to detect circulating tumor DNA in cancer patients through a blood sample. This test analyzes 74 clinically relevant genes, offering key insights for personalized cancer treatment.

With over 24 years of experience and 50,000 genetic tests conducted, Strand Life Sciences has developed the SA74 LB Test to ensure high accuracy and sensitivity using Unique Molecular Identifiers (UMIs). The test’s deep coverage, with over 15,000x pre-UMI and 2,000x post-UMI analysis, enhances its precision in detecting genetic variants. Strand’s CAP and NABL-accredited labs ensure the highest quality standards, adhering to international best practices.

The SA74 LB Test provides actionable insights by identifying genomic alterations in genes associated with solid tumor therapies, in line with FDA and NCCN guidelines. Its minimally invasive approach, requiring only a peripheral blood sample, makes it a convenient option for patients, particularly when traditional biopsies are not feasible or when tissue samples are insufficient.

According to the company, the SA74 LB Test is a significant advancement in cancer diagnostics, helping clinicians make timely, informed decisions to optimize treatment plans and improve patient outcomes. "This test makes genetic testing more accessible and beneficial to patients, showcasing Strand Life Sciences' commitment to advancing precision medicine," said Dr. Ramesh Hariharan, CEO of Strand Life Sciences.